SenescentImmune Cells Drive Mucin Glycan Loss, Blocking Akkermansia Colonization and Fueling Inflammaging

Hypothesis

Senescent CD8⁺ T lymphocytes in the aged colonic lamina propria secrete matrix metalloproteinase‑9 (MMP‑9) that selectively strips O‑glycan side chains from Muc2 mucin, converting a permissive mucus niche into a barrier that cannot support Akkermansia muciniphila colonization. This glycan loss precedes mucus thinning and directly fuels inflammaging by exposing peptide cores that act as damage‑associated molecular patterns (DAMPs) for resident macrophages.

Mechanistic Basis

• Immune‑derived MMP‑9 accumulates with age and correlates with senescent T‑cell markers (p16^INK4a^, SA‑β‑gal) in mouse and human colon.
• MMP‑9 cleaves the protein backbone near serine/threonine residues, releasing O‑glycan fragments that are normally used by Akkermansia as carbon sources.
• The resulting mucin core is more prone to bacterial protease degradation, increasing permeability and allowing translocation of microbial products that activate TLR4 on macrophages, perpetuating cytokine release (IL‑6, TNF‑α) and further T‑cell senescence.
• Thus, immune senescence is not a passive by‑product but an active enzyme‑driven destructor of the mucus glycan scaffold.

Testable Predictions

1. Correlation: In aged mice, the frequency of p16^INK4a^⁺ CD8⁺ T cells will inversely correlate with colonic Muc2 O‑glycan density (measured by lectin blotting) and directly correlate with MMP‑9 activity in lamina propria extracts.
2. Causality: Genetic ablation of MMP‑9 specifically in CD8⁺ T cells (CD8‑Cre;Mmp9^fl/fl) will preserve O‑glycan structure, increase mucus permeability resistance, and allow spontaneous Akkermansia colonization without exogenous supplementation.
3. Rescue: Administering a selective MMP‑9 inhibitor to aged wild‑type mice will restore mucin O‑glycan profile, reduce serum LPS‑binding protein, and lower inflammatory cytokines, mimicking the effects of senolytic clearance of senescent T cells.
4. Human relevance: Colon biopsies from older individuals with high circulating senescent T‑cell frequencies will show reduced Muc2 O‑glycan staining and elevated MMP‑9 immunoreactivity compared with younger controls.

Experimental Design

• Mouse models: Use Ercc1−/Δ accelerated aging model and aged wild‑type C57BL/6J. Flow cytometry to identify p16^INK4a^⁺ CD8⁺ T cells. Gelatin zymography and fluorogenic MMP‑9 substrate assays on isolated lamina propria lymphocytes.
• Glycan analysis: Perform β‑elimination followed by mass spectrometry to quantify O‑glycan disaccharides on purified Muc2. Use lectin (WFA, PNA) staining on colonic sections for spatial read‑out.
• Microbiota: Quantify Akkermansia by qPCR of 16S rRNA and FISH; assess mucus thickness with confocal microscopy of labeled mucin.
• Interventions: (a) CD8‑specific MMP‑9 knockout, (b) pharmacological MMP‑9 inhibitor (SB‑3CT), (c) senolytic (navitoclax) to clear senescent T cells. Compare mucus glycan integrity, Akkermansia colonization, permeability (FITC‑dextran assay), and cytokine panels.
• Read‑outs: If predictions hold, only conditions that remove MMP‑9 activity or senescent CD8⁺ T cells will rescue O‑glycans, enable Akkermansia engraftment, and dampen inflammaging. Failure to observe these changes would falsify the hypothesis.

This framework shifts the focus from merely thickening mucus to preserving its glycan code, positioning senescent immune‑derived proteolysis as the upstream lever that, when targeted, could re‑establish a healthy Akkermansia‑mucus axis before broader systemic aging phenotypes manifest.